Nitazoxanide (NSC 697855)

Catalog No.S1627 Synonyms: NTZ

For research use only.

Nitazoxanide (NTZ, NSC 697855) is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent(IC50 for canine influenza virus ranges from 0.17 to 0.21 μM). Nitazoxanide modulates autophagy and inhibits mTORC1 signaling.

Nitazoxanide (NSC 697855) Chemical Structure

CAS No. 55981-09-4

Selleck's Nitazoxanide (NSC 697855) has been cited by 6 Publications

Purity & Quality Control

Choose Selective Influenza Virus Inhibitors

Biological Activity

Description Nitazoxanide (NTZ, NSC 697855) is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent(IC50 for canine influenza virus ranges from 0.17 to 0.21 μM). Nitazoxanide modulates autophagy and inhibits mTORC1 signaling.
Targets
PFOR [2]
()
mTORC1 [6]
()
In vitro

Nitazoxanide reduces parasite growth in cell culture by more than 90% with little evidence of drug-associated cytotoxicity. [1] Nitazoxanide is a new thiazolide antiparasitic agent that shows excellent in vitro activity against a wide variety of protozoa and helminths. [2] Nitazoxanide and its metabolite tizoxanide are more active in vitro than metronidazole against G. intestinalis, E. histolytica and T. vaginalis. [3] Nitazoxanide exhibits potent inhibition of both HBV and HCV replication. Nitazoxanide potentiates the effect of subsequent treatment with Nitazoxanide plus IFN, but not Nitazoxanide plus 2'CmeC, in HCV replicon-containing cells. Nitazoxanide induces reductions in several HBV proteins (HBsAg, HBeAg, HBcAg) produced by 2.2.15 cells, but does not affect HBV RNA transcription. [4] Nitazoxanide exhibits IC50, and IC90 values of 0.017 and 0.776 mg/mL respectively, against E. histolytica, 0.004 and 0.067 mg/mL against G. intestinalis, and 0.034 and 2.046 mg/mL against T. vaginalis. Nitazoxanide is more toxic than metronidazole and albendazole against E. histolytica. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2(2.2.15) M3HUeWFvfGm4aYLhcEBie3OjeR?= NGDudVBCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJ\XCjdHn0bZMhSiC4aYL1d{Bqdm[nY4Tl[EBqdiCqdX3hckBJ\XCJMjiyMlIvOTVrIHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJIV5fHKjY3XscJVt[XJidnnyZYwhTE6DIH3lZZN2emWmIEK0JIhzeyCjZoTldkBt[XO2IHTvd4UtKEWFNUC9NE4yOs7:TR?= M3O2elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUWzPFEzLz5{MUW1N|gyOjxxYU6=
HepG2(2.2.15) NHzXWWRCdnSrdnnyZYwh[XO|YYm= NIHzWZNCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJSlZiaX7m[YN1\WRiaX6gbJVu[W5iSHXwS|IpOi5{LkG1LUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHX4eJJi[2WubIXsZZIhfmm{YXygSG5CKGyndnXsMEBKSzVyPUCuNVLPxE1? M3XURlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{izNlc1Lz5{OEO4N|I4PDxxYU6=
Ava5 MkfoRY51cX[rcnHsJIF{e2G7 MojnN{Bl[Xm| NFrFVpZCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJS1ZiZ3Xuc5R6eGViMXKgbY5n\WO2ZXSgbY4hSX[jNTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFMh\GG7czDifUBjdG:2IHj5ZpJq\Gm8YYTpc44h[W6jbInzbZMtKEWFNUC9NE4zOc7:TR?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB3OUm4N{c,OjJyNUm5PFM9N2F-
Huh7.5 MUHBcpRqfmm{YXygZZN{[Xl? MkPpN{Bl[Xm| Moq1RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGNXKGenbn;0fZBmKDGjIHnu[oVkfGWmIHnuJGh2cDdwNTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFMh\GG7czDifUBjdG:2IHj5ZpJq\Gm8YYTpc44h[W6jbInzbZMtKEWFNUC9NE4{O87:TR?= NGq3d3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC1PVk5Oyd-MkKwOVk6QDN:L3G+
HepG2(2.2.15) NVjZVGdJSW62aY\pdoFtKGG|c3H5 M3WwVWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhmeGG2aYTpd{BDKH[rcoXzJIlv\mWldHXkJIlvKGi3bXHuJGhmeEd{KEKuNk4yPSliY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gbY51emGlZXzseYxieiC4aYLhcEBFVkFibXXhd5Vz\WRiMkSgbJJ{KGGodHXyJIxie3RiZH;z[UwhTUN3ME2wMlU6|ryP M3i1T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUWzPFEzLz5{MUW1N|gyOjxxYU6=
HepG2(2.2.15) MUTBcpRqfmm{YXygZZN{[Xl? NGK5N2hCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJ\XCjdHn0bZMhSiC4aYL1d{Bqdm[nY4Tl[EBqdiCqdX3hckBJ\XCJMjiyMlIvOTVrIHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJIV5fHKjY3XscJVt[XJidnnyZYwhTE6DIH3lZZN2emWmIEK0JIhzeyCjZoTldkBt[XO2IHTvd4UtKEWFOUC9NE45O87:TR?= Mlf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NUO4NVIoRjJzNUWzPFEzRC:jPh?=
Ava5 NULl[IhRSW62aY\pdoFtKGG|c3H5 MVmzJIRigXN? M{LlOGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhEXiCpZX7veJlx\SBzYjDpcoZm[3SnZDDpckBCfmF3IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgN{Bl[Xm|IHL5JIJtd3RiaInidollcXqjdHnvckBidmGueYPpd{whTUN7ME2wMlk{|ryP M2Swc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEW5PVg{Lz5{MkC1PVk5OzxxYU6=
Huh7.5 M{XPbGFvfGm4aYLhcEBie3OjeR?= MVqzJIRigXN? MYrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIR3Yh\2Wwb4T5dIUhOWFiaX7m[YN1\WRiaX6gTJVpPy53IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgN{Bl[Xm|IHL5JIJtd3RiaInidollcXqjdHnvckBidmGueYPpd{whTUN7ME2xMlHPxE1? NYK0bJFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwOVk6QDNpPkKyNFU6QTh|PD;hQi=>
BHK-21 NXrrNZdSSW62aY\pdoFtKGG|c3H5 MXrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDDbIlsfW6pdX75ZUB3cXK3czCwOlEy[VS5IHnu[oVkfGWmIHnuJGJJUy1{MTDj[YxteyCkeTDSWE1yWEOUIHHuZYx6e2m|LDDFR|UxRTFwOUdOwG0> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6OUm3OUc,Ojh4OEm5O|U9N2F-
HepG2(2.2.15) MWrBcpRqfmm{YXygZZN{[Xl? MnG4RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTIVx[XSrdHnzJGIhfmm{dYOgbY5n\WO2ZXSgbY4hcHWvYX6gTIVxTzJqMj6yMlE2MSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDpcpRz[WOnbHz1cIFzKH[rcnHsJGRPSSCvZXHzeZJm\CB{NDDodpMh[W[2ZYKgcIF{fCCmb4PlMEBGSzlyPUKuNe69VQ>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV3M{ixNkc,OjF3NUO4NVI9N2F-
HCT8 NYmyeY1NSW62aYDhdoF{cXSrYzDhd5NigQ>? NWHjNIw1PDhiaILz NHzBcmRCdnSrcHHyZZNqfGmlIHHjeIl3cXS7IHHnZYlve3RiQ4L5dJRwe3CxcnnkbZVuKHCjco\1cUBUWExiaX7m[YN1\WRiaX6gbJVu[W5iSFPUPEBk\WyuczDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCISWTDM2RCWElic4ThbY5qdmdiYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwQVIvO87:TR?= NHXhcJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
Vero E6 MVTGeY5kfGmxbjDhd5NigQ>? MV:0PEBpenN? NWPDOIE{UUN3MDDmc5Ih[W62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhW0GUUz3Dc3YuOiCrbjD0bIUhXmW{bzDFOkBk\WyuIHzpcoUh[XRiNEigbEBjgSCrbX31co9ndHWxcnXzZ4Vv[2VvYnHz[YQh[XO|YYmgLIRmfGWldHnu[{B1cGVidnnyZYwhVlBicILveIVqdiCrbjD0bIUhdnWlbHX1d{Bw\iC2aHWgWoVzdyCHNjDj[YxteyluIFnDOVA:Oi56MUizPO69VQ>? NEHvZZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MkO1N|g2QSd-M{KzOVM5PTl:L3G+
HCT8 NIjSXotCdnSrcHHyZZNqfGmlIHHzd4F6 M{XjPVQ5KGi{cx?= MUTBcpRqeGG{YYPpeIlkKGGldHn2bZR6KGGpYXnud5QhS3K7cITvd5BwemmmaYXtJJBien[3bTDCS2YhcW6oZXP0[YQhcW5iaIXtZY4hUEOWODDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBHUVSFL1TBVGkhe3SjaX7pcoch[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5MEBGSzVyPUKuPe69VQ>? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4OUW3OUc,Ojl2Nkm1O|U9N2F-
BHK-21 Ml;KRY51cX[rcnHsJIF{e2G7 NWDocIROSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhcW6oZXP0[YQhcW5iQljLMVIyKGOnbHzzJIJ6KFKWLYHQR3Ih[W6jbInzbZMtKEWFNUC9Nk46Ps7:TR?= M2HRdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Nki5PVc2Lz5{OE[4PVk4PTxxYU6=
U2OS MXTBcpRqfmm{YXygZZN{[Xl? MYLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDDbIlsfW6pdX75ZUB3cXK3czDpcoZm[3SnZDDpckBpfW2jbjDVNm9UKGOnbHzzJIJ6KFKWLYHQR3Ih[W6jbInzbZMtKEWFNUC9N{4xOc7:TR?= Mm\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEm5O|UoRjJ6Nki5PVc2RC:jPh?=
HCT8 NV\tTIhlSW62aYDhdoF{cXSrYzDhd5NigQ>? NHjzV4JCdnSrcHHyZZNqfGmlIHHjeIl3cXS7IHHnZYlve3RiQ4L5dJRwe3CxcnnkbZVuKHCjco\1cUBqdiCKQ2S4JINmdGy|LDDJR|UxRTNwMkZOwG0> NWDYepRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0PFAzQDFpPkG2OFgxOjhzPD;hQi=>
HCT-8 MYLBcpRqdWmlcn;ibYFtKGG|c3H5 NFPITHdCdnSrbXnjdo9jcWGuIHHjeIl3cXS7IHHnZYlve3RiQ4L5dJRwe3CxcnnkbZVuKHCjco\1cUBqdm[nY4Tl[EBqdiCqdX3hckBJS1RvODDj[YxteyxiSVO1NF0{NjkQvF2= NXzH[XE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVEzQDBpPkG4OVkyOjhyPD;hQi=>
BHK-21 MlzQRY51cX[rcnHsJIF{e2G7 NUXBPGI3SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhODhzMHLUe{Bqdm[nY4Tl[EBqdiCESFutNlEh[2WubIOgZpkhWlRvcWDDVkBidmGueYPpd{whTUN3ME20Mlk2|ryP MmX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEm5O|UoRjJ6Nki5PVc2RC:jPh?=
Vero NWLqRWJSS3m2b4TvfIlkcXS7IHHzd4F6 NGfPfGI1QCCqcoO= MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBi\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCZU2StNUBie3OjeTygTWM2OD1zMD63OO69VQ>? NG\xelc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4O|I5QSd-MkO3PFczQDl:L3G+
BHK21 NX\5OIYyS3m2b4TvfIlkcXS7IHHzd4F6 M{PCbFE3KGi{cx?= M4fBXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKKS{KxJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjCxOkBpenNiYomgR2NMNThiYYPzZZktKEOFNUC9NlXPxE1? NYSzNHN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PFk6PzVpPkK4Olg6QTd3PD;hQi=>
U2OS M1K5cWN6fG:2b4jpZ4l1gSCjc4PhfS=> MWixOkBpenN? NUPCTpRIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTKRUzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiMU[gbJJ{KGK7IFPDT{05KGG|c3H5MEBESzVyPUK1{txO NIjrfWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4PVk4PSd-Mki2PFk6PzV:L3G+
Ava5 MXzDfZRwfG:6aXPpeJkh[XO|YYm= NXX0Vpp1OyCmYYnz MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBeoE2KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDu[ZV1emGuIILl[EBlgWViYYPzZZktKEOFNUC9N|XPxE1? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB3OUm4N{c,OjJyNUm5PFM9N2F-
Huh7.5 Mnm2R5l1d3SxeHnjbZR6KGG|c3H5 M2DkWFMh\GG7cx?= MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeYg4NjViY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JI5mfXS{YXygdoVlKGS7ZTDhd5NigSxiQ1O1NF01Qc7:TR?= M33YOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEW5PVg{Lz5{MkC1PVk5OzxxYU6=
DAOY Mnz5dWhVWyCjc4PhfS=> NX7sd|VoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 NUfkZ2E1eUiWUzDhd5NigQ>? NFfScmJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NH33NIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 MXHxTHRUKGG|c3H5 MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? NWeybXpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 NGPhfVlyUFSVIHHzd4F6 MkTydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| M{GxdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 NVPUTFEzeUiWUzDhd5NigQ>? NGT4WZpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 NHrNR|VyUFSVIHHzd4F6 MoTadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= Moi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 M2eydpFJXFNiYYPzZZk> Mo\6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NUW3TFFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 NEDXRZNyUFSVIHHzd4F6 MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? M2O1U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 NH;yUXRyUFSVIHHzd4F6 M{nGbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= M4O2c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 M4H6OZFJXFNiYYPzZZk> M37tdJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy| NHjzU289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 NXLxe2xkeUiWUzDhd5NigQ>? NFTJWoJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz MnW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD MX3xTHRUKGG|c3H5 NH;qTGVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? NYLBXHVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
In vivo

Nitazoxanide is partially effective at reducing the parasite burden in a gnotobiotic piglet diarrhea model when given orally for 11 days at 250 mg/kg/day but not at 125 mg/kg/day. Nitazoxanide induces a drug-related diarrhea in piglets that might have influenced its therapeutic efficacy. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 62 mg/mL
(201.77 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 307.28
Formula

C12H9N3O5S

CAS No. 55981-09-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01529073 Unknown status Drug: Nitazoxanide HCV Coinfection|HIV Infection Juan Macías|Spanish National Health System|Andaluz Health Service February 2012 Phase 2
NCT01197157 Completed Drug: Placebo|Drug: Nitazoxanide Hepatitis C National Liver Institute Egypt September 2010 Phase 2|Phase 3

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Nitazoxanide (NSC 697855) | Nitazoxanide (NSC 697855) ic50 | Nitazoxanide (NSC 697855) price | Nitazoxanide (NSC 697855) cost | Nitazoxanide (NSC 697855) solubility dmso | Nitazoxanide (NSC 697855) purchase | Nitazoxanide (NSC 697855) manufacturer | Nitazoxanide (NSC 697855) research buy | Nitazoxanide (NSC 697855) order | Nitazoxanide (NSC 697855) mouse | Nitazoxanide (NSC 697855) chemical structure | Nitazoxanide (NSC 697855) mw | Nitazoxanide (NSC 697855) molecular weight | Nitazoxanide (NSC 697855) datasheet | Nitazoxanide (NSC 697855) supplier | Nitazoxanide (NSC 697855) in vitro | Nitazoxanide (NSC 697855) cell line | Nitazoxanide (NSC 697855) concentration | Nitazoxanide (NSC 697855) nmr